Hemcheck has received a follow-up order from Kuressaare Hospital in Estonia, regarding hemolysis detection in connection with blood gas analysis. The order is for bgs-Test and is of lower economic value, but important as it is a follow-up order that comes close after the initial order.
– It is promising with a follow-up order so close to the initial order, even if it is of lower economic value. Since the first order was for v-Test and this order is for bgs-Test, it is also clear that the hospital wants to evaluate our products in additional areas of usage, says Joen Averstad, CEO of Hemcheck.
For further information contact:
Hemcheck Sweden AB (publ)
Joen Averstad, CEO
Tel: +46 76 108 8191
About Kuressaare hospital
Read more at https://www.saarehaigla.ee/
Hemcheck Sweden AB, founded in 2010, produces and commercializes a patented CE-marked concept for point of care hemolysis detection. The concept consists of disposable tests as well as readers that can very quickly, directly upon sampling, identify hemolysed blood samples in vacuum tubes and blood gas syringes. Hemolysis, ruptured red blood cells, is the most common reason globally why blood samples cannot be analyzed accurately and is also a biomarker for acute medical conditions. Hemcheck’s goal is to contribute to improved healthcare by offering user-friendly solutions for the detection of hemolysed blood samples in direct connection with blood sampling near the patient. By doing so, Hemcheck can contribute to increased patient safety, more efficient processes and lower costs. The company is listed on the Nasdaq First North Growth Market.
FNCA Sweden AB, 08-528 00 399, info@fnca, is the Certified Adviser to the company.